Zevra Therapeutics (NASDAQ:ZVRA) Price Target Lowered to $23.00 at Guggenheim

Zevra Therapeutics (NASDAQ:ZVRA) had its target price reduced by Guggenheim from $24.00 to $23.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also issued research reports about the stock. Citizens Jmp increased their target price on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of Zevra Therapeutics in a research note on Tuesday, June 23rd. UBS Group restated a “buy” rating on shares of Zevra Therapeutics in a research report on Wednesday, June 24th. Maxim Group raised their price objective on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Finally, BTIG Research decreased their price objective on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, July 27th. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $27.14.

Zevra Therapeutics Trading Down 2.7%

Shares of NASDAQ ZVRA opened at $11.56 on Friday. The stock’s 50-day moving average is $12.32 and its 200 day moving average is $10.58. The stock has a market cap of $686.43 million, a price-to-earnings ratio of 12.57 and a beta of 0.91. Zevra Therapeutics has a 1-year low of $7.16 and a 1-year high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.14. The business had revenue of $39.66 million during the quarter, compared to analyst estimates of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. On average, analysts forecast that Zevra Therapeutics will post 0.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new stake in Zevra Therapeutics in the 2nd quarter worth $2,846,000. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Zevra Therapeutics by 116.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after purchasing an additional 206,543 shares during the period. Quantinno Capital Management LP boosted its holdings in shares of Zevra Therapeutics by 114.1% during the first quarter. Quantinno Capital Management LP now owns 32,022 shares of the company’s stock worth $298,000 after purchasing an additional 17,065 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Zevra Therapeutics by 259.2% in the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after purchasing an additional 400,336 shares during the last quarter. Finally, AIGH Capital Management LLC bought a new stake in shares of Zevra Therapeutics in the first quarter worth about $11,184,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

More Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Zevra reported quarterly EPS of $0.25 versus the $0.11 consensus estimate, while revenue reached $39.66 million, above expectations of $33.88 million. The company also posted a 42.82% net margin and positive operating cash flow. Zevra Therapeutics quarterly earnings report
• Positive Sentiment: Analysts remain bullish. Citizens raised its price target from $25 to $28 and assigned a “market outperform” rating. HC Wainwright maintained a “Buy” rating and a $26 target, while increasing its FY2026 EPS forecast to $0.57 from $0.55. Citizens price-target update
• Positive Sentiment: Regulatory and intellectual-property developments could improve MIPLYFFA’s long-term outlook. Zevra outlined a timeline for a CHMP reexamination opinion expected in the fourth quarter, while its MIPLYFFA Orange Book listing reportedly extends to 2041. Zevra CHMP and Orange Book update
• Neutral Sentiment: Guggenheim trimmed its price target to $23 from $24 but retained a “Buy” rating, leaving a target substantially above the current trading level. Guggenheim price-target update
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to $0.13 from $0.17, signaling weaker near-term earnings expectations despite raising its full-year forecast.
• Negative Sentiment: Pomerantz LLP is investigating potential claims on behalf of ZVRA investors. Although no allegations or findings were detailed, the announcement introduces legal and reputational overhang. Pomerantz investor investigation

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.